Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has received a consensus rating of “Moderate Buy” from the five ...

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting ...

Actinium Pharmaceuticals (ATNM) announced that the first clinical trial under its previously announced Cooperative Research and Development ...

Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga ...

In a report released yesterday, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research ...

In a challenging year for Actinium Pharmaceuticals (NYSE:ATNM), the company's stock has touched a 52-week low, trading at $1.1, marking an 80% decline from its 52-week high of $10.24. According to ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

Actinium-225 PSMA therapy is an emerging treatment for advanced prostate cancer that focuses on delivering targeted radiation ...

Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ...